COMPANY
NextPoint Therapeutics
Funding and NIH signals
- SEC Form D raise Raised $33.73M (Form D filed Jul 30, 2026). SEC Form D 0001959209-26-000002 (Jul 30, 2026)
Evidence (1 event)
- Jul 30, 2026 · SEC Form D 0001959209-26-000002
Name of Issuer: NextPoint Therapeutics, Inc.; CIK: 1959209; Address: Cambridge, MA; Submission type: D; Filing date: 2026-07-30; Industry Group: Biotechnology; Date of First Sale: 2026-07-22; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 48729165; Total Amount Sold: 33728772; Federal exemptions: 06b
- Jul 30, 2026 · SEC Form D 0001959209-26-000002
Timeline
- Trial start Phase 1: NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies source ↗
- Trial start Phase 1: A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2 source ↗
- Trial start Phase 1: A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7 source ↗
Upcoming milestones
- Apr 1, 2027 (ESTIMATED) · Phase 1 · NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies · NCT07563829
- 2027-08 (ESTIMATED) · Phase 1 · A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2 · NCT06240728
Clinical trials (lead sponsor) 3
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07563829 | NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies | Phase 1 | Recruiting | May 1, 2026 | Apr 1, 2027 (estimated) |
| NCT05958199 | A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7 | Phase 1 | Suspended | Jul 21, 2023 | Sep 20, 2025 (estimated) |
| NCT06240728 | A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2 | Phase 1 | Recruiting | Jan 22, 2024 | 2027-08 (estimated) |
Raises and investors new
- InvestorListed in the portfolio of MPM BioImpact (captured Oct 12, 2026). portfolio page ↗